anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prepare a novel alcoholic product in a short time, by extracting the aboveground part or underground root of a vegetable widely known to have physiological and pharmacological usefulness, separating a fructose-containing extract therefrom, adding distilled liquor thereto, and aging the mixture. CONSTITUTION:The above ground part (fruit, SHIITAKE, polypore, etc.) or the underground root (e.g. rhizome of Panax ginseng, bulb of garlic, etc.) of a vegetable known to have physiological or pharmaceutical usefulness or at least to be harmless, is mixed with or immersed in crystalline fructose or liquid fructose to obtain a fructose- containing vegetable extract taking advantage of the impregnating and water-absorbing activity of fructose. The extract or its mixture is added with distilled liquor and aged to obtain an alcohlic product. Compared with the process to make an alcoholic drink directly from the vegetable, the preparation time of the present process preparing a fructose-containing extract as an intermediate is shortened to 1/2. The process has excellent economicity and productivity, and since the obtained extract is free from alcohol, it is suitable for the production in foreign countries, and the product can be freely imported or exported.
A ketamine bolus of 0.5mg/kg will be given and then the ketamine infusion of 0.2 mg/kg/hr will be initiated prior to incision. Intra-operative opioids will be at the discretion of the attending anesthesiologist. Postoperative management will include continuation of the study drug as well as a standardized morphine patient-controlled analgesia (PCA) and acetaminophen 15 mg/kg IV every 6 hours. On postoperative day 1, patients are started on ketorolac 0.5 mg/kg up to 15 mg IV q8h. On postoperative day 2 they are transitioned to ibuprofen 10 mg/kg up to 600 mg. The ketamine infusion will continue for 48 hours post operatively at which point the PCA is discontinued and patients are transitioned to oral pain medications (Roxicet or Lortab and Flexeril) as per the current protocol.
Only a few cases describing the activity of dermestids on human corpses have been reported in the literature. Dermestes maculatus is a cosmopolitan beetle associated with carcasses at different decomposition stages, usually colonizing skeletonized and mummified remains. In this study, we presented two forensic case reports of D. maculatus associated with human corpses in Santa Catarina State, southern Brazil. In the first case, a human corpse in an advanced stage of decomposition was found hanged in an outdoor urban area. In the other one, a mummified cadaver was found inside of a closed house. In this last case, larvae of D. maculatus were essential to estimate the minimum postmortem interval (PMI) for the first time in Scientific Police of Santa Catarina. Our records highlight the significance of necrophagous beetles in ecological succession and in estimating PMI in cases involving human remains and corpses in advanced stage of decomposition.
An antimicrobial composition of buckminsterfullerene with gallium phosphonate functional groups (520) is provided to disassemble or make virus particles (540) inert, and to inhibit viral and fungal proteases using catalytic desulfurization. This composition (520) prevents and inactivates novel corona viruses including variant strains of SARS-Cov-2, fungal pathologies such as valley fever, respiratory ailments such as chronic obstructive pulmonary disorder (COPD), pneumonia, and arthropod vectored bacterial pathogens such as Lyme disease. The antiviral properties further prevent conditions leading to uncontrolled cellular proliferation, neoplasms, degenerative malignancy, cancers, and chronic inflammatory diseases. The gallium similarity to iron permits the treatment of osteoporosis, hypertension, and thrombosis by depolymerizing fibrin in the dissolution of clots and restoration of vascular plasticity. The composition (520) can be produced at low temperatures through reactive shear milling. Delivery methods include ingestion, topical application, inhalation, or injection when used as a medicament or as a food supplement.
The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
A homeopathic skin card is a novel means of utilisation of already existing homeopathic products. In effect, a homeopathic product acts by emanating a curative activity over a certain distance. The homeopathic skin card is an assembly of 2 or 3 (or more) sealed bags inside one another, containing a neutral, flat support having a defined area of a certain number of square centimetres, bearing the homeopathic product or products. The primary bag containing the support and the homeopathic product must be made of a neutral synthetic plastic, for example polyethylene, incapable of modifying the curative activity of the card. This card must be deformable and incapable of being torn, safe and capable of moulding itself to the contours of the body. The final, surface bag containing the labelling should be pierced with 2 holes in order to wear the homeopathic skin card, by means of a cord, either as a pendant or as a periumbilical girdle.
Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). If the mobile ECG shows possible AF or unclassified, then patients will undergo a 12-lead standard ECG during the same visit, read by a cardiologist, to verify the correct diagnosis.
OBJECTIVE: Deciduous dental crowns primarily develop during gestation and early infancy and embody early life stress exposures. Composite measures of dental fluctuating asymmetry (DFA) generated from the deciduous teeth may therefore indicate cumulative gestational stress in developmental origins of health and disease (DOHaD) studies. This study examines whether higher composite measures of deciduous DFA are associated with low birthweight and prematurity, two aspects of birth phenotype consistently associated with increased morbidity and mortality risks in adulthood.
SUBJECTS AND METHODS: We evaluated associations between composite deciduous DFA, birthweight, and birth term in two contemporary North American samples: an autopsy sample from New Mexico (n = 94), and sample from a growth cohort study in Burlington, Ontario (n = 304). Dental metric data for each sample was collected from postmortem CT scans and dental casts, respectively. Composite DFA was estimated using buccolingual (BL) and mesiodistal (MD) crown diameters from paired deciduous teeth.
RESULTS: Contrary to expectations, the results of linear regression indicated no significant relationship between birthweight and DFA, or birth term and DFA, in either sample.
CONCLUSIONS: Deciduous DFA does not predict aspects of birth phenotype associated with gestational stress. Birthweight and birth term are plastic relative to the more developmentally stable deciduous dentition, which may only subtly embody early life stress. We suggest that deciduous DFA should be utilized with caution in DOHaD studies until its relationship with gestational stress is clarified.
FIELD: medicine. SUBSTANCE: method involves distributing healing remedy which is thought to be bee wax covering at least one carrier surface or placed into the carrier pores or bee wax applied as film or granules. The coating is produced as bee wax layer that is optionally used autonomously or spread over a carrier on one or both sides, or impregnating porous carrier. The wax can contain curative additions. EFFECT: enhanced effectiveness of treatment. 30 cl, 6 dwg
Several international registries have reported on the efficacy of caplacizumab for the treatment of immune thrombotic thrombocytopenic purpura (iTTP). Similar real-world data from the United States (US) are limited. In this single center retrospective study, we sought to describe caplacizumab prescribing patterns and review clinical outcomes for US patients with iTTP. Subjects were eligible for inclusion if they were diagnosed with acute iTTP and received care at University of Pittsburgh Medical Center-affiliated hospitals from 2012 to 2022. Subjects were divided into an historical cohort who received standard of care therapy alone, and early and late administration cohorts (EA and LA) who received caplacizumab within and greater than 72 h of admission, respectively, plus standard of care. Clinical data were collected from the electronic record. Thirty-two subjects were included: 16 historical, 12 EA, and 4 LA subjects. Refractoriness occurred more frequently in the LA and historical cohorts as compared to the EA cohort (4 (100%) vs. 6 (38%) vs. 3 (25%), p = 0.02). The LA cohort also experienced longer lengths of hospital stay, required more TPE procedures, and were exposed to the greatest amount of donor plasma (p < 0.05 for all) as compared to the other cohorts. Time to platelet count normalization was longest in the LA cohort (p = 0.013). There were no significant between-group differences in bleeding events. Because we are unable to predict which patients will develop refractoriness, we recommend frontline administration of caplacizumab to all patients with iTTP.
OBJECTIVE: To prospectively investigate the course of epilepsy and assess seizure control during pregnancy in women with focal epilepsy (FE) compared with generalized epilepsy (GE), to ascertain the effects of epilepsy and its types on delivery and neonatal outcomes, and to compare adverse outcomes between pregnancies complicated by epilepsy and normal pregnancies.
METHODS: 124 pregnant women with epilepsy (WWE) were enrolled in a prospective study. Obstetric and neonatal outcomes were compared with those of 277 healthy women in the control group.
RESULTS: Occurrence of seizures during pregnancy was more often in FE (77.1 %) compared with GE (50.0 %) (Odds ratio [OR] 2.08; 95 % confidence interval [CI] 0.97-4.46, p = 0.06); the overall seizure freedom was significantly higher in women with GE compared with women with FE (p = 0.0038). Poor seizure control one year prior to the pregnancy and nonadherence to treatment were significantly associated with presence of seizures during pregnancy (p < 0.0001). Compared with pregnancies of women without epilepsy, WWE were at increased risk of cesarean section (CS) (p < 0.0001) and preterm birth (p = 0.03). Offspring of mothers with epilepsy were at higher risks of Apgar scores at 5 min ≤7 (p < 0.0001) and perinatal hypoxia (p = 0.03) compared with infants of unaffected women. Seizures during pregnancy were significantly correlated with the higher rate of CS, Apgar scores at 5 min ≤7, and perinatal hypoxia (p = 0.0069; p = 0.0098; and p = 0.0045, respectively). The risks of adverse outcomes were not significantly increased in women with FE compared to women with GE.
CONCLUSION: Epileptic seizures in pregnancy are associated with increased risks of adverse delivery and neonatal outcomes. Hence, early assessment of seizure disorder, adequate seizure control prior to and during pregnancy, and effective treatment are required to prevent potential seizure-related complications and improve maternal and fetal outcomes.
Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
The present invention relates to an apparatus and method for presenting medical alerts. The apparatus comprises a medical device, a patient sensor, a signal processing unit and an output unit. The signal processing unit receives measurements of the patient sensor and generates a plurality of signals by evaluating the received measurements. The signal processing unit determines whether a predefined alarm criterion, which relates to the signal, is fulfilled and detects an alarm and the moment of the alarm. The signal processing unit controls the output unit. The manipulated output unit presents the alarm in the total time period in an alarm-total sequence and the alarm in the reference time window in an alarm-reference-section and in an alarm-reference-sequence, and the time profile of at least one signal in the reference time window in a signal profile-diagram. The reference-time window is a segment of the total-time period. The manipulated output unit presents the temporal positioning of the alarm-reference-section relative to the alarm-total-sequence.
The invention relates to a tolterodine tartrate film-controlled slow-release pellet capsule. A slow-release film of the tolterodine tartrate film-controlled slow-release pellet utilizes a mixture of aqueous dispersion Eurdragit RL 30D and Eurdragit RS 30D as a film-formation material, wherein a weight ratio of Eurdragit RL 30D to Eurdragit RS 30D in the mixture is 9: 1. A pellet core of the tolterodine tartrate film-controlled slow-release pellet contains low-substituted hydroxypropyl cellulose having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose and lactose, and the pellet core comprises 10 to 40wt% of the low-substituted hydroxypropyl cellulose. The slow-release film comprises the mixture of Eurdragit RL 30D and Eurdragit RS 30D, triethyl citrate as a plasticizer, and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to Eurdragit RS 30D to triethyl citrate to talcum powder is 27: 3: 2: 4 and coating weight gain is in a range of 19 to 34%. The tolterodine tartrate film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxypropyl cellulose having high water expansibility and thus after absorbing water, the tolterodine tartrate film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the tolterodine tartrate film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept prior to expiration date.
The use of Conray may be beneficial in the image enhancement of non-neoplastic lesions. General infarctions of recent onset may be better visualized with the contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60% of cerebral infarctions studied from one to four weeks from the onset of symptoms. 

Sites of active infection may also be enhanced following contrast medium administration. 

Arteriovenous malformations and aneurysms will show contrast enhancement. In the case of these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. 

The opacification of the inferior vermis following contrast medium administration has resulted in false positive diagnoses in a number of normal studies.
Vitamin A supplementation (VAS) to children above 6 months of age reduces all-cause mortality with 23 %1 to 30 % in low-income countries. WHO recommends VAS at vaccination contacts. The currently recommended doses to be administered every 3-6 months are 100,000 IU for infants between 6 and 11 months of age and 200,000 IU for children 12 months and older. There is no clear evidence that a large dose is better than a small dose, the tendency being the opposite in the two studies of different doses of VAS that have been published so far.

With the global effort to eradicate polio, national immunization days with oral polio vaccine (OPV) offer an additional opportunity to provide vitamin A. In Guinea-Bissau, a combined OPV and VAS campaign took place in November 2002. Given the uncertainty about the best dose of VAS, we aimed to examine whether the dose of vitamin A currently recommended by WHO or half this dose gives a better protection against childhood morbidity and mortality.
Among the various psychological properties of the decision making process is temporal discounting, which is a decrease in the subjective value of a good as a function of the amount of and delay to reward. The ability to decide between immediate versus future rewards depends on self-control and consideration of the future. We can reconceptualize suicide as intertemporal discounting with an interaction between cognition and mood. Someone contemplating suicide weighs the time value of costs and benefits with shifting negative and positive valence systems. To the best of our knowledge, no one has assessed the interaction between mood symptoms, anxiety, and their impact on the temporal discounting paradigm in bipolar patients. If we better understood the difference between anxious, suicidal and non-anxious, suicidal bipolar patients, we could design more effective interventions to prevent this tragic outcome. We propose a novel paradigm to explore the link between bipolar disorder, anxiety, and suicide. If we conceptualize suicidal behavior and death by suicide as decisions, then it makes sense to examine key aspects of decision making in these patients. In particular, we can examine how mood, anxiety, and suicidal ideation and behaviors arise from patterns of decision making, along with neural correlates of decision-making, as assessed with fMRI.
Narcolepsy type 1 (NT1) is an uncommon, persistent sleep disorder distinguished by significant daytime sleepiness, episodes of cataplexy, and irregularities in rapid eye movement sleep. The etiology of NT1 is linked to the destruction of hypothalamic neurons responsible for the synthesis of the wake-promoting neuropeptide known as hypothalamic orexin. The pathophysiological mechanisms underlying NT1 remain inadequately elucidated; however, a model that incorporates the interplay of genetic predisposition, environmental influences, immune system factors, and a deficiency in hypocretin (HCRT) provides a framework for elucidating the pathogenesis of NT1. The prevalence of NT1 has been observed to rise following influenza A (H1N1) pdm09 and the administration of the Pandemrix influenza vaccine. The strong association between narcolepsy and the HLA-DQB1*06:02 allele strongly indicates an autoimmune etiology for this condition. Increasing evidence suggests that T cells play a critical role in this autoimmune-mediated HCRT neuronal loss. Studies have identified specific T cell subsets, including CD4+ and CD8+ T cells, that target HCRT neurons, contributing to their destruction. Clarifying the pathogenesis of NT1 driven by autoimmune T cells is crucial for the development of effective therapeutic interventions for this disorder. This review examines the risk factors associated with the pathogenesis of NT1, explores the role of T cells within the immune system in the progression of NT1, and evaluates immune-mediated animal models alongside prospective immunotherapeutic strategies.
PCT No. PCT/IB97/01092 Sec. 371 Date May 13, 1998 Sec. 102(e) Date May 13, 1998 PCT Filed Sep. 12, 1997 PCT Pub. No. WO98/13447 PCT Pub. Date Apr. 2, 1998The compounds of formula in which R stands for a methyl or ethyl group, are used as perfume ingredients for the preparation of perfuming compositions and perfumed articles, to which they confer aromatic and thujonic notes. The compounds can be used in the form of a mixture of enantiomers or in an enantiomerically pure state. The invention also comprises original processes for the preparation of these compounds.
Coatings to enhance the echogenicity of materials are especially useful for medical devices wherein the practitioner desires to locate or visualize a device by ultrasonic imaging when the device is inserted into a body cavity. These coatings can be applied to any device of virtually any composition. To accomplish this, a polymer matrix is formed containing an entrapped gas in enclosed bubbles or open surface channels or cavities. Coated needles are visible in ultrasound when inserted in animals. A pre-coat or base coat may be applied to condition the surface to enhance adhesion. A finish coat or top coat may be applied to improve durability, smoothness, and biocompatibility, lubricity, antibiotic, antimicrobial, antithrombogenic activity, and other desirable properties for the finished product. Coating liquids and methods for preparing and applying such coatings are disclosed, including forming bubbles by chemical reaction during the coating process.
AF is the most prevalent arrhythmia, affecting \>2 million Americans. Antiarrhythmic drug therapy often is ineffective to eliminate recurrent episodes of AF. In recent years radiofrequency catheter ablation has emerged as a highly effective treatment strategy in patients with paroxysmal and chronic AF.6, 7 However, AF may recur within days to weeks after a successful ablation procedure in up to 50% of the patients, probably because of an inflammatory response to thermal injury caused by radiofrequency energy application. These early recurrences of AF after ablation do not necessarily predict long-term clinical outcome and 30-50% of patients who develop early recurrences ultimately remain in sinus rhythm without the need for additional ablation.8 However, early recurrences of AF may be associated with significant morbidity due to troubling symptoms of rapid ventricular rates, multiple hospital visits and cardioversions, need for antiarrhythmic drug therapy and prolongation in duration of anticoagulant therapy. It is also possible that if early recurrences of AF after ablation can be avoided, the probability of remaining in sinus rhythm during long-term follow-up may be higher, as maintenance of sinus rhythm early-on may facilitate reverse left atrial remodeling. A similar phenomenon may occur in post-operative AF, that develops in \~30% of patients who undergo cardiac surgery. Post-operative AF is often transient and usually resolves within 3 months after the surgery. Perioperative treatment with omega-3 fatty acids has been reported to decrease the incidence of postoperative AF after coronary artery by-pass surgery.4 Because the pathogenetic factors that play a role in postoperative AF and early recurrences of AF after radiofrequency catheter ablation may be similar, it is plausible that treatment with omega-3 fatty acids before and after ablation will be associated with a reduction in the incidence of early recurrences of AF.
PURPOSE:To provide a keratin-softening plaster by compounding an adhesive base agent with salicylic acid, lanolin and a fatty acid alkyl ester. CONSTITUTION:An adhesive agent is compounded with 10-50wt.% of salicylic acid and with a lanolin and a fatty acid alkyl ester in a ratio of 1:9 to 9:1. Concretely, when the salicylic acid is e.g. 10wt.%, the lanolin and the fatty acid alkyl ester are compounded in a total amount of 3-40wt.%, and when the salicylic acid is 40wt.%, the lanolin and the fatty acid alkyl ester is compounded in a total amount of 1-35wt.%. The ingredients are mixed with each other, and the obtained keratin-softening plaster can be coated on a support such as a cloth or film to provide a keratin-softening patch. The keratin- softening patch can shorten the curing time of a lesion in comparison with conventional salicylic acid-compounded patches and does not require to be fixed to the lesion over a long time.